The Study Of Vaccination Of NogoA Combined With Olfactory Ensheathing Glia Implantation In Treatment Of Acute Spinal Cord Injury

Objective : OEG has bigeminal character of Schwann and Astrocytes, so it can compensate the defect of Schwann cells On one hand, OEG can product NTs such as NGF, BDNF, NT-3, NT-4 et al. So OEG is able to promote the regenerating of axons ni spinal cord injury(SCI). But, distal from the injury site was still limited partly because of the inhibitor released in the area of SCI. NogoA is one of the most important factor in the inhibition of regeneration of axons. The study that antibody to NogoA, IN-1, can block the effect of NogoA and promote the regeneration of axons has been reported. Many studies are focused on the usage of IN-1 to stimulate nerve regeneration, but the safe and the short half-life of exogenous antibody is still a problem. In our study, the polypeptide of NogoA is used as antigen to make the treatment vaccination of NogoA. Rats were inmmuned with this vaccinaltion and can secret the antibody against NogoA before the SCI. The antibody can block the NogoA as the damage of the barrier between the blood and brain. In the same time, OEG transplantation were applied in the management of spinal contusion model to increase the promoting agents. The present study provide a new strategy of combined methods for the SCI, and attempt to enhance regeneration and gain th balance of microenvironment.Methods: Artifical NogoA 13 polypeptide coupled with KLH to improve the immunogenicity of vaccination. Rats received abdominal cavity immunization before the injury of spinal cord. The level of antibody and the binding capability were detected with ELISA. The safety of vaccination was evaluated by the incidence and severity of EAE. OEG were purified and subsequently implanted into adult Wistar rats directly after contusion of the thoracic spinal cord (T9). In 12weeks, the ethology of animal, histology were compared among the vaccinaltion, OEG, simple injured, and combined treatment group.Results: The antibody against the polypeptide had been detected with ELISA. The features of EAE were not found in the immunized rats. At 3 months after injury, BBB Score and the count of neuro fibers in BDA nerve tracing and anti-NF dyeing of combined treatment group were significantly better than the other groups.Conclusion: NogoA polypeptide vaccination can stimulate the antibody against the polypeptide. The binding reaction can be reveal in the ex vivo experiment. The safety of vaccination were revealed by no features of EAE found in the immunized rats. The combined stratey of OEG and NogoA vaccination may be better than simple mothod for the regeneration of axons and recovery of function in the contusion animal model of SCI.